Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study [Yahoo! Finance]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Yahoo! Finance
Corvus Pharmaceuticals soared by 211.8 percent week-on-week to hit a new all-time high, as investors cheered the strong results of its clinical trial testing the efficacy of soquelitinib in patients with moderate to severe eczema. On Friday alone, the stock jumped to its highest price of $26.95 before giving up all gains to end the session down by 1.65 percent at $25.10 apiece. In an updated report earlier in the week, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) said that its drug candidate successfully demonstrated a 72 percent reduction in the severity of enrolled patients' eczema in the first phase trial, as compared with the 40 percent reduction for those who took the placebo. Additionally, the therapy was observed to be even more effective when taken longer, and it was well-tolerated by enrolled patients. Based on the positive results, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) is planning to initiate a Phase 2 trial in the first quarter of 2026 and enroll 200 patients with
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]Yahoo! Finance
- Assessing Corvus Pharmaceuticals (CRVS) Valuation After Rapid Multi-Year Share Price Gains [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals (CRVS) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $33.00 price target on the stock, up from $32.00.MarketBeat
- Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
CRVS
Earnings
- 3/12/26 - Miss
CRVS
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/13/26 - Form 8-K
- 3/13/26 - Form 424B5
- CRVS's page on the SEC website